Sirukumab: A novel therapy for lupus nephritis?

Uma Thanarajasingam, Timothy B. Niewold

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Introduction: Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatment strategies for LN.

Original languageEnglish (US)
Pages (from-to)1449-1455
Number of pages7
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - Oct 1 2014


  • Biologic
  • Human
  • IL-6
  • Lupus nephritis
  • Monoclonal antibody
  • Sirukumab
  • Systemic lupus erythematosus
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sirukumab: A novel therapy for lupus nephritis?'. Together they form a unique fingerprint.

Cite this